trivalent influenza vaccine (The University of Hong Kong)

I-The University of Hong Kong-influenza refers to the trivalent influenza vaccine (TIV) interventions evaluated in clinical research conducted by The University of Hong Kong. Specifically, this identifier is associated with a Phase 4 comparative study (NCT01442441) investigating the safety and immunogenicity of intradermal (ID) versus intramuscular (IM) administration of TIV in institutionalized older adults. The study utilized commercially available vaccines, specifically Sanofi Pasteur's Intanza (intradermal) and Vaxigrip (intramuscular). Trivalent influenza vaccines are designed to induce active immunity against three strains of the influenza virus—typically two Type A strains (H1N1 and H3N2) and one Type B strain—by targeting the viral hemagglutinin protein. The research aimed to determine if the intradermal route, which targets the immune-cell-rich dermis, could provide superior protection in elderly populations affected by immune senescence.

Brand names

IntanzaVaxigripIDflu

Other names

TIVtrivalent inactivated influenza vaccineseasonal influenza vaccine